Codiak BioSciences, Inc. Stock-Based Compensation
Codiak BioSciences, Inc. reported Stock-Based Compensation of $7.30 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2022-11-03
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-09-30 was $2.29M, a 26.03% decline year-over-year.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-06-30 was $2.67M, a 0.82% decline year-over-year.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2022-03-31 was $2.35M, a 3.34% increase year-over-year.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2021-12-31 was $2.09M, a 1.51% decline year-over-year.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for fiscal 2021 was $10.14M, a 43.25% increase from fiscal 2020.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for fiscal 2020 was $7.08M, a 2.28% decline from fiscal 2019.
- Codiak BioSciences, Inc. share-based payment arrangement, noncash expense for fiscal 2019 was $7.25M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.96M derived: sum of 2 quarters · filed 2022-11-03 | $7.30M 10-Q · filed 2022-11-03 | $9.39M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.02M 10-Q · filed 2022-08-04 | $7.10M derived: sum of 3 quarters · filed 2022-08-04 | $10.20M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-03-31 | $2.35M 10-Q · filed 2022-05-05 | $4.44M derived: sum of 2 quarters · filed 2022-05-05 | $7.53M derived: sum of 3 quarters · filed 2022-11-03 | $10.22M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $5.18M derived: sum of 2 quarters · filed 2022-11-03 | $7.87M derived: sum of 3 quarters · filed 2022-11-03 | $10.14M 10-K · filed 2022-03-10 |
| 2021-09-30 | $3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.78M derived: sum of 2 quarters · filed 2022-11-03 | $8.05M 10-Q · filed 2022-11-03 | $10.17M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.96M 10-Q · filed 2022-08-04 | $7.08M derived: sum of 3 quarters · filed 2022-08-04 | $8.90M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.27M 10-Q · filed 2022-05-05 | $4.39M derived: sum of 2 quarters · filed 2022-05-05 | $6.21M derived: sum of 3 quarters · filed 2022-05-05 | $7.60M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.94M derived: sum of 2 quarters · filed 2022-03-10 | $5.33M derived: sum of 3 quarters · filed 2022-03-10 | $7.08M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.21M derived: sum of 2 quarters · filed 2021-11-04 | $4.96M 10-Q · filed 2021-11-04 | $7.32M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.14M 10-Q · filed 2021-08-05 | $5.50M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.75M 10-Q · filed 2021-05-06 | $4.11M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | $7.25M 10-K · filed 2021-03-17 | ||
| 2019-09-30 | $4.88M 10-Q · filed 2020-11-19 |